[New immunomodulator for multiple sclerosis patients. 30% fewer relapse rates].
D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D020528:Multiple Sclerosis, Chronic Progressive / Q000175:diagnosis / Q000188:drug therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy*; D009460:Neurologic Examination / Q000187:drug effects; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate
Neuer Immunmodulator für Multiple-Sklerose-Patienten. 30% niedrigere Schubrate.